Clinical Trial Update: Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

View source ↗

Summary

A completed clinical trial evaluating the predictive value of the BreathID 13C-Methacetin breath test for hepatic decompensation in chronic liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Decompensation
• Liver Disease

Snippet

Sponsor: Meridian Bioscience, Inc. | Conditions: Chronic Liver Disease | Status: COMPLETED | Results posted: 2019-09-27